Lyra Therapeutics Inc
NASDAQ:LYRA
Lyra Therapeutics Inc
NASDAQ:LYRA
Price:
0.3558 USD
-4.35%
Updated:
May 16, 2024
Lyra Therapeutics Inc
Cash from Investing Activities
|
Lyra Therapeutics Inc
Cash from Investing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Lyra Therapeutics Inc
NASDAQ:LYRA
|
Cash from Investing Activities
-$12.6m
|
CAGR 3-Years
-92%
|
CAGR 5-Years
-216%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Investing Activities
-$2.9B
|
CAGR 3-Years
48%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Investing Activities
-$21.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Investing Activities
-$32.3B
|
CAGR 3-Years
-76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Investing Activities
-$13.1B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Investing Activities
-$7.6B
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
See Also
What is Lyra Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
-12.6m
USD
-12.6m
USD
Based on the financial report for Dec 31, 2023, Lyra Therapeutics Inc's Cash from Investing Activities amounts to -12.6m USD.
What is Lyra Therapeutics Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-216%
-216%
Over the last year, the Cash from Investing Activities growth was 81%. The average annual Cash from Investing Activities growth rates for Lyra Therapeutics Inc have been -92% over the past three years , -216% over the past five years .
You don't have any saved screeners yet
